FDA: Start sleep drug lunesta at lower dose for safety - 8 News NOW

FDA: Start sleep drug lunesta at lower dose for safety

© iStockphoto.com / Jacob Wackerhausen © iStockphoto.com / Jacob Wackerhausen

THURSDAY, May 15, 2014 (HealthDay News) -- Some users of the popular sleep medicine Lunesta remain too drowsy for safety during the day, and the recommended starting dose for the medicine should be lowered, the U.S. Food and Drug Administration said on May 15.

In a statement, the agency said it took the action due to studies showing that levels of Lunesta (eszopiclone) in some patients may remain high enough in the morning to interfere with driving and other activities that require them to be mentally alert.

This impairment can occur even if patients feel fully awake, the FDA said.

"To help ensure patient safety, health care professionals should prescribe, and patients should take, the lowest dose of a sleep medicine that effectively treats their insomnia," Dr. Ellis Unger, director of the Office of Drug Evaluation I in the FDA's Center for Drug Evaluation and Research, said in the FDA news release.

The recommended starting dose of Lunesta -- taken at bedtime -- has been reduced from 2 milligrams (mg) to 1 mg for both women and men, which means that less of the drug will remain in the body the next morning.

The dose can be increased to 2 mg or 3 mg if needed, but those higher doses are more likely to reduce alertness the next morning, the FDA noted.

The agency advised that patients who are currently taking 2-mg or 3-mg doses of Lunesta discuss the issue with their doctor, deciding on how to keep taking the drug safely and at a dose that best suits them.

One of the studies cited by the FDA included 91 healthy adults, aged 25 to 40. It found that currently recommended doses of Lunesta could hamper driving skills, memory and coordination for as long as 11 hours after taking the drug. Despite these effects, patients often did not realize they were impaired.

Prescribing information on Lunesta's label will be changed, and the same changes must be made to the labels of generic versions of eszopiclone, the FDA said. The agency also wants doctors to caution patients taking Lunesta about the risk of impaired alertness the next morning.

Next-day drowsiness is a common side effect of all insomnia drugs, the FDA noted.

In 2013, the agency ordered a dose reduction for sleep drugs with the active ingredient zolpidem, such as Ambien and Ambien CR.

More information

The U.S. National Library of Medicine has more about insomnia.

Copyright © 2014 HealthDay. All rights reserved.

  • Paula's Health NotesLas Vegas Health NewsMore>>

  • New procedure to help Lipedema

    New procedure to help Lipedema

    Friday, August 22 2014 3:55 PM EDT2014-08-22 19:55:58 GMT
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>
  • Fixing gerd for good

    Fixing gerd for good

    Tuesday, August 19 2014 3:21 PM EDT2014-08-19 19:21:39 GMT
    Acid reflux disease, a condition commonly known as “GERD”, affects about one-third of Americans. It can cause pain, coughing, heartburn and can even lead to cancer. Now, a simple procedure may fix GERD for good.More>>
    Acid reflux disease, a condition commonly known as “GERD”, affects about one-third of Americans. It can cause pain, coughing, heartburn and can even lead to cancer. Now, a simple procedure may fix GERD for good.More>>
  • Ice cold heart therapy

    Ice cold heart therapy

    Friday, August 15 2014 5:05 PM EDT2014-08-15 21:05:13 GMT
    A trial fibrillation affects about 2.7 million Americans. It's a condition that causes heart palpitations, shortness of breath and dizziness. If left untreated, it can be life-threatening. Now doctors are freezing the problem away.More>>
    A trial fibrillation affects about 2.7 million Americans. It's a condition that causes heart palpitations, shortness of breath and dizziness. If left untreated, it can be life-threatening. Now doctors are freezing the problem away.More>>
*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KLAS. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.